Stock analysts at BMO Capital Markets initiated coverage on shares of DexCom Inc. (NASDAQ:DXCM) in a research note issued on Friday. The firm set an “outperform” rating and a $112.00 price target on the medical device company’s stock. BMO Capital Markets’ price target suggests a potential upside of 20.35% from the company’s previous close.

DXCM has been the subject of several other reports. Leerink Swann reissued an “outperform” rating and issued a $90.00 price objective on shares of DexCom in a research note on Wednesday, July 20th. BTIG Research downgraded DexCom from a “buy” rating to a “neutral” rating and set a $92.00 price objective for the company. in a research note on Wednesday, September 14th. Canaccord Genuity reissued a “buy” rating and issued a $95.00 price objective on shares of DexCom in a research note on Wednesday, July 13th. Desjardins raised DexCom from a “hold” rating to a “buy” rating in a research note on Friday. Finally, Piper Jaffray Cos. reissued an “overweight” rating and issued a $93.00 price objective on shares of DexCom in a research note on Friday, July 15th. Four research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $94.96.

DexCom (NASDAQ:DXCM) opened at 93.06 on Friday. DexCom has a 12-month low of $47.92 and a 12-month high of $100.72. The firm has a 50-day moving average price of $91.81 and a 200-day moving average price of $75.54. The stock’s market cap is $7.81 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.12. The business earned $137.30 million during the quarter, compared to analysts’ expectations of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The firm’s revenue was up 47.3% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) earnings per share. Analysts forecast that DexCom will post ($0.57) EPS for the current fiscal year.

In other news, CEO Kevin R. Sayer sold 7,000 shares of DexCom stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $91.79, for a total transaction of $642,530.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Jorge A. Valdes sold 19,071 shares of DexCom stock in a transaction that occurred on Monday, September 12th. The stock was sold at an average price of $93.07, for a total value of $1,774,937.97. Following the sale, the insider now directly owns 103,667 shares in the company, valued at approximately $9,648,287.69. The disclosure for this sale can be found here. 2.80% of the stock is owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Wellington Management Group LLP raised its stake in shares of DexCom by 227.1% in the first quarter. Wellington Management Group LLP now owns 5,747,553 shares of the medical device company’s stock valued at $390,316,000 after buying an additional 3,990,578 shares during the last quarter. FMR LLC raised its stake in shares of DexCom by 59.3% in the second quarter. FMR LLC now owns 8,161,390 shares of the medical device company’s stock valued at $647,443,000 after buying an additional 3,036,821 shares during the last quarter. Janus Capital Management LLC raised its stake in shares of DexCom by 1,808.4% in the second quarter. Janus Capital Management LLC now owns 1,725,218 shares of the medical device company’s stock valued at $136,860,000 after buying an additional 1,634,818 shares during the last quarter. Waddell & Reed Financial Inc. raised its stake in shares of DexCom by 91.6% in the second quarter. Waddell & Reed Financial Inc. now owns 2,175,574 shares of the medical device company’s stock valued at $172,589,000 after buying an additional 1,040,279 shares during the last quarter. Finally, Artisan Partners Limited Partnership raised its stake in shares of DexCom by 22.0% in the second quarter. Artisan Partners Limited Partnership now owns 5,591,101 shares of the medical device company’s stock valued at $443,542,000 after buying an additional 1,008,260 shares during the last quarter. 99.50% of the stock is currently owned by institutional investors.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.